Literature DB >> 8356025

Renal handling of carnitine in secondary carnitine deficiency disorders.

C A Stanley1, G T Berry, M J Bennett, S M Willi, W R Treem, D E Hale.   

Abstract

Reduced plasma and tissue concentrations of carnitine, a cofactor required for fatty acid oxidation, are present in patients with inherited disorders of mitochondrial acyl-CoA oxidation that are associated with accumulations of acylcarnitines. To determine whether the secondary carnitine deficiency in these patients is due to excessive urinary loss of acylcarnitines, the development of carnitine deficiency was examined in patients with four different acyl-CoA oxidation disorders, including medium-chain and long-chain fatty acyl-CoA dehydrogenase deficiencies, isovaleric acidemia, and propionic acidemia. After a 3-mo period of treatment with oral carnitine to raise plasma total carnitine concentrations to or above normal, patients were started on a carnitine-free diet and the changes in plasma total and free carnitine levels and urinary total and free carnitine excretion were followed for 5 d. Patients with all four disorders showed a return of plasma carnitine levels and urinary carnitine excretion to baseline within 2 to 4 d. The rapidity of these changes could not be explained solely by excessive acylcarnitine wasting. Continued excretion of free carnitine in all patients indicated the additional presence of an impairment in renal transport of free carnitine. Consistent with this interpretation, estimates of renal thresholds for free carnitine gave values that were less than that for a control child in all four disorders and ranged as low as one half those reported in normal individuals. These results suggest that secondary carnitine deficiency in the acyl-CoA oxidation disorders is due to indirect as well as direct effects of accumulated acylcarnitines.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8356025     DOI: 10.1203/00006450-199307000-00021

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  10 in total

1.  Improvements of hypertriglyceridemia and hyperlacticemia in Japanese children with glycogen storage disease type Ia by medium-chain triglyceride milk.

Authors:  Hironori Nagasaka; Ken-ichi Hirano; Akira Ohtake; Takashi Miida; Tomozumi Takatani; Kei Murayama; Tohru Yorifuji; Kunihiko Kobayashi; Masaki Kanazawa; Atsushi Ogawa; Masaki Takayanagi
Journal:  Eur J Pediatr       Date:  2007-01-06       Impact factor: 3.183

Review 2.  L-Carnitine.

Authors:  J H Walter
Journal:  Arch Dis Child       Date:  1996-06       Impact factor: 3.791

3.  Clinical and biochemical findings in a Spanish boy with primary carnitine deficiency.

Authors:  P Briones; B Garavaglia; A Ribes; M E Yoldi; M Rodés; C Romero; F García-Bragado
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

Review 4.  Carnitine deficiency-induced cardiomyopathy.

Authors:  D J Paulson
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

5.  Medium-chain triglyceride loading test in carnitine-acylcarnitine translocase deficiency: insights on treatment.

Authors:  R Parini; F Invernizzi; F Menni; B Garavaglia; D Melotti; M Rimoldi; S Salera; C Tosetto; F Taroni
Journal:  J Inherit Metab Dis       Date:  1999-08       Impact factor: 4.982

6.  Acylcarnitine profile in tissues and body fluids of biotin-deficient rats with and without L-carnitine supplementation.

Authors:  Y Shigematsu; I L Bykov; Y Y Liu; A Nakai; Y Kikawa; M Sudo; M Fujioka
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

Review 7.  Methylmalonic and propionic acidemias: clinical management update.

Authors:  Jamie L Fraser; Charles P Venditti
Journal:  Curr Opin Pediatr       Date:  2016-12       Impact factor: 2.856

8.  Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity.

Authors:  S Krähenbühl; G Mang; H Kupferschmidt; P J Meier; M Krause
Journal:  Gut       Date:  1995-07       Impact factor: 23.059

Review 9.  Pharmacokinetics of L-carnitine.

Authors:  Allan M Evans; Gianfranco Fornasini
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Disorders of branched chain amino acid metabolism.

Authors:  I Manoli; C P Venditti
Journal:  Transl Sci Rare Dis       Date:  2016-11-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.